Comment je traite... une onychomycose par voie topique.

[en] Onychomycosis is a frequent and challenging disease to treat. Well conducted oral therapies are commonly quite effective for a short term period. However, recurrences are frequent. Topical therapies appear globally less active. Studies in this field are rare, although the promotional advertisements to the general public abound nowadays. Various microscopic fungi (dermatophytes, yeasts, molds) should be targeted by the treatment, In addition, the distinct activity conditions of both growth and quiescence of the pathogen fungi should be influenced by the treatments. This is not frequently considered by drug companies and encountered in practice. The antifungal drug penetration inside all the nail layers is important to be performed.

Disciplines :

Dermatology

Author, co-author :

Pierard, Gérald ; Université de Liège > Département des sciences cliniques > Département des sciences cliniques

Pierard-Franchimont, Claudine ; Université de Liège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques

Language :

French

Title :

Comment je traite... une onychomycose par voie topique.

Alternative titles :

[en] How I treat... onychomycosis by topical therapy

Publication date :

2015

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

5-11

Peer reviewed :

Peer reviewed

Available on ORBi :

since 30 May 2015

Statistics

Number of views

150 (3 by ULiège)

Number of downloads

1376 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Ghannoum MA, Hajjeh RA, Scher R, et al.- A largescale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol, 2000, 43, 641-648.
Monod M, Lurati M, Baudraz-Rosselet F.- Diagnosis of non dermatophyte onychomycosis ant its relevance for treatment. Rev Med Suisse, 2013, 9, 730-733.
Nir-Paz R, Elinav H, Piérard GE, et al.- Deep infection by Trichophyton rubrum in an immunocompromised patient. J Clin Microbiol, 2003, 41, 5298-5301.
Ghannoum MA, Rice LB.- Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev, 1999, 12, 501-517.
Baran R, Gupta AK, Piérard GE.- Pharmacotherapy of onychomycosis. Expert Opin Pharmacother, 2005, 6, 609-624.
Alley MR, Baker SJ, Beutner KR, et al.- Recent progress on the topical therapy of onychomycosis. Expert Opin Investig Drugs, 2007, 16, 157-167.
Elewski B, Pariser D, Rich P, et al.- Current and emerging options in the treatment of onychomycosis. Semin Cutan Med Surg, 2013, 32, S9-12.
Piérard GE, Piérard-Franchimont C.- The nail under fungal siege in patients with type II diabetes mellitus. Mycoses, 2005, 48, 339-342.
Piérard-Franchimont C, Kharfi M, Piérard GE.- Prélèvement et examen mycologiques des onychomycoses. In: Onychomycoses. Ed. Baran R, Piérard GE. Publ. Abrégés Masson, Paris, 2004, 79-90.
Piérard GE.- In vivo confocal microscopy : a new paradigm in dermatology. Dermatology, 1993, 186, 4-5.
Corcuff P, Gonnord G, Piérard GE, et al.- In vivo confocal microscopy of human skin : a new design for cosmetology and dermatology. Scanning, 1996, 18, 351-355.
De Doncker P, Decroix J, Piérard GE, et al.- Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol, 1996, 132, 34-41.
De Doncker PR, Scher RK, Baran RL, et al.- Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 36 patients. J Am Acad Dermatol, 1997, 36, 173-177.
Piérard GE, Piérard-Franchimont C, Arrese JE.- The boosted oral antifungal treatment for onychomycosis beyond the regular itraconazole pulse dosing regimen. Dermatology, 2000, 200, 185-187.
Sigurgeirsson B, Olafsson JH, Steinsson JB, et al.-Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis : a 5-year blinded prospective follow-up study. Arch Dermatol, 2002, 138, 353-357.
Osborne CS, Leitner I, Favre B, et al.- Antifungal drug response in an in vitro model of dermatophyte nail infection. Med Mycol, 2004, 42, 159-163.
Gupta AK, Katz HI, Shear NH.- Drug interactions with itraconazole, fluconazole, and terbinafine and their management. J Am Acad Dermatol, 1999, 41, 237-249.
Ceschin-Roques CG, Hanel H, Pruja-Bougaret SM, et al.- Ciclopirox nail lacquer 8% : in vivo penetration into and through nails and in vitro effect on pig skin. Skin Pharmacol, 1991, 4, 89-94.
Marty JP.- Amorolfine nail lacquer : a novel formulation. J Eur Acad Dermatol Venereol, 1995, 4, S17-S21.
Gupta AK, Fleckman P, Baran R.- Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol, 2000, 43, S70-80.
Gupta AK.- Ciclopirox : an overview. Int J Dermatol, 2001, 40, 305-310.
Fleckman P.- Onychomycosis : diagnosis and topical therapy. Dermatol Ther, 2002, 15, 71-77.
Gupta AK, Plott T.- Ciclopirox : a broad-spectrum antifungal with antibacterial and anti-inflammatory properties. Int J Dermatol, 2004, 43 Suppl 1, 3-8.
Flagothier C, Piérard-Franchimont C, Piérard GE.-New insights into the effect of amorolfine nail lacquer. Mycoses, 2005, 48, 91-94.
Jarratt M, Siu WJ, Yamakawa E, et al.- Safety and pharmacokinetics of efinaconazole 10% solution in healthy volunteers and patients with severe onychomycosis. J Drugs Dermatol, 2013, 12, 1010-1016.
Gupta AK, Paquet M.- Efinaconazole 10% nail solution: a new topical treatment with broad antifungal activity for onychomycosis monotherapy. J Cutan Med Surg, 2014, 18, 151-155.
Scher RK, Nakamura N, Tavakkol A.- Luliconazole: a review of a new antifungal agent for the topical treatment of onychomycosis. Mycoses, 2014, 57, 389-393.
Kobayashi Y, Komatsu T, Sumi M, et al.- In vitro permeation of several drugs through the human nail plate: relationship between physicochemical properties and nail permeability of drugs. Eur J Pharm Sci, 2004, 21, 471-477.
Monti D, Tampucci S, Chetoni P, et al.- Ciclopirox vs amorolfine: in vitro penetration into and permeation through human healthy nails of commercial nail lacquers. J Drugs Dermatol, 2014, 13, 143-147.
Piérard GE.- Spores, sporodochia and fomites in onychomycosis. Dermatology, 2006, 213, 169-172.
Owais M, Ansari MA, Ahmad I, et al.-Innate immunity in pathogenesis and treatment of dermatomycosis. In : Combating fungal infections. Ed. Ahmad I, Owais M, Shahid M, Aqil F. Publ. Springer, Heidelberg., 2010, 347-371.
Piérard GE, Piérard-Franchimont C, Arrese JE.- The boosted antifungal topical treatment (BATT) for onychomycosis. Med Mycol, 2000, 38, 391-392.
Cantoresi F, Caserini M, Bidolli A, et al.- Randomized controlled trial of a water-soluble nail lacquer based on hydroxypropyl-chitosan (HPCH), in the management of nail psoriasis. Clin Cosmet Invest Dermatol, 2014, 7, 185-190.
Lim EH, Kim HR, Park YO, et al.- Toenail onychomycosis treated with a fractional carbon-dioxide laser and topical antifungal cream. J Am Acad Dermatol, 2014, 70, 918-923.
Piérard GE, Arrese JE, Pierre S, et al.- Diagnostic microscopique des onychomycoses. Ann Dermatol Vénérol, 1994, 121, 25-29.